This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

Radionuclide Therapy

Targeted Radionuclide Therapy or Peptide Receptor Radionuclide Therapy (PRRT) is a medical specialty in nuclear medicine using very small amounts of radioactive materials, called radiopharmaceuticals, to diagnose and treat various diseases, like cancer. Targeted radiopharmaceuticals in molecular therapy contain a targeting molecule and a medical radioisotope complexed with a chelating agent. 

The targeting molecule binds to the tumor specific receptor according to the lock and key principle. In most cases the targeting molecule can be used for both diagnostics and therapy - only the radioisotope has to be changed. This opens up the way for the application of Theranostics in the field of Precision Oncology. The technique works by injecting into the patient’s body the targeted radiopharmaceuticals that accumulate in the affected organs or lesions. 

For diagnostic applications radioisotopes with short half-lives are used. With highly sensitive molecular imaging technologies like PET (Positron Emission Tomography) or SPECT (Single Photon Emission Tomography), pictures of organs and lesions can be created and therefore, diseases can be diagnosed in their early stages.

Medical radioisotopes with longer half-lives are applied for treatment. To destroy the tumor, cytoxic doses of ionizing radiation have to be submitted to the tumor site before decay. A highly precise localization of the toxicity ensures that healthy tissue in the surroundings of the targeted tumor is minimally affected.

Advantages of Targeted Radionuclide Therapy in Precision Oncology

  • Solid tumors such as neuroendocrine tumors (NETs), prostate cancer or bone metastases can be detected at an early stage by in vivo imaging
  • In most cases the targeting molecule can be used for diagnostics as well as for radionuclide therapy. This opens up the way for the application of Theranostics
  • Specific tumors are dealt by precision diagnostic and therapeutic radiopharmaceuticals in the most effective manner
  • Targeted Radionuclide Therapy as a treatment option where other therapies are limited or even fail